Russia's 2nd Coronavirus Vaccine Candidate Enters Phase 3 Study

Announced on October 5, 2020, nearly 30,000 volunteers will take part in post-registration trials of the EpiVacCorona coronavirus vaccine developed by Russia's Vector State Research Center of Virology and Biotechnology, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.